{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:04:06Z","timestamp":1772445846454,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22cm0106381 and 25ama22134"],"award-info":[{"award-number":["22cm0106381 and 25ama22134"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JPJSBP120237202 and JP20H03710"],"award-info":[{"award-number":["JPJSBP120237202 and JP20H03710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04342-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:14:27Z","timestamp":1772442867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T cells derived from a novel, high-affinity anti-CLL-1 monoclonal antibody exhibit a significant anti-AML effect"],"prefix":"10.1007","volume":"75","author":[{"given":"Shuhei","family":"Kida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"11","key":"4342_CR1","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Riviere I, Sadelain M (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41(11):1871\u20131891. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.010","journal-title":"Cancer Cell"},{"issue":"1","key":"4342_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29668-9","volume":"13","author":"M Sugita","year":"2022","unstructured":"Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, Yip W, Filipe S, Lebuhotel C, Gouble A, Hassane DC, Smith J, Roboz GJ, Guzman ML (2022) Allogeneic TCRalphabeta deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun 13(1):2227. https:\/\/doi.org\/10.1038\/s41467-022-29668-9","journal-title":"Nat Commun"},{"issue":"12","key":"4342_CR3","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI (2024) Cytokine-mediated CAR T therapy resistance in AML. Nat Med 30(12):3697\u20133708. https:\/\/doi.org\/10.1038\/s41591-024-03271-5","journal-title":"Nat Med"},{"issue":"18","key":"4342_CR4","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ (2013) T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122(18):3138\u20133148. https:\/\/doi.org\/10.1182\/blood-2012-12-474056","journal-title":"Blood"},{"issue":"12","key":"4342_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","volume":"95","author":"V Marin","year":"2010","unstructured":"Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E (2010) Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95(12):2144\u20132152. https:\/\/doi.org\/10.3324\/haematol.2010.026310","journal-title":"Haematologica"},{"issue":"8","key":"4342_CR6","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D (2014) Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28(8):1596\u20131605. https:\/\/doi.org\/10.1038\/leu.2014.62","journal-title":"Leukemia"},{"issue":"3","key":"4342_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2014.112748","volume":"100","author":"C O\u2019Hear","year":"2015","unstructured":"O\u2019Hear C, Heiber JF, Schubert I, Fey G, Geiger TL (2015) Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 100(3):336\u2013344. https:\/\/doi.org\/10.3324\/haematol.2014.112748","journal-title":"Haematologica"},{"issue":"6","key":"4342_CR8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu K-R, Kenderian SS, Ruella M, Chen S, Shin T-H, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S (2018) Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173(6):1439-1453.e1419. https:\/\/doi.org\/10.1016\/j.cell.2018.05.013","journal-title":"Cell"},{"issue":"24","key":"4342_CR9","doi-asserted-by":"publisher","first-page":"11978","DOI":"10.1073\/pnas.1819992116","volume":"116","author":"F Borot","year":"2019","unstructured":"Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, Mukherjee S (2019) Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci U S A 116(24):11978\u201311987. https:\/\/doi.org\/10.1073\/pnas.1819992116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4342_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009013","author":"R Freeman","year":"2024","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, Um JS, Tanaka K, Cai W, Yoo S, Dunbar A, Park Y, McAvoy D, Hosszu KK, Levine RL, Boelens JJ, Lorenz IC, Brentjens RJ, Daniyan AF (2024) Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009013","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4342_CR11","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG (2021) Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35(11):3282\u20133286. https:\/\/doi.org\/10.1038\/s41375-021-01232-2","journal-title":"Leukemia"},{"key":"4342_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","author":"ML Baroni","year":"2020","unstructured":"Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, de la Diaz Guardia R, Castano J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P (2020) 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000845","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4342_CR13","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, van Stigter- Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110(7):2659\u20132666. https:\/\/doi.org\/10.1182\/blood-2007-03-083048","journal-title":"Blood"},{"issue":"22","key":"4342_CR14","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.Can-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radosevic K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, Kruisbeek AM (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64(22):8443\u20138450. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-1659","journal-title":"Cancer Res"},{"issue":"9","key":"4342_CR15","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK (2017) Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther 25(9):2202\u20132213. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.024","journal-title":"Mol Ther"},{"key":"4342_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001229","author":"P Ataca Atilla","year":"2020","unstructured":"Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, Simons BW, McLean Stevens A, Redell MS, Heslop HE, Mamonkin M, Brenner MK, Atilla E (2020) Modulating TNF\u03b1 activity allows transgenic IL15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001229","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4342_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.14104","volume":"112","author":"XY Wang","year":"2024","unstructured":"Wang XY, Bian MR, Lin GQ, Yu L, Zhang YM, Wu DP (2024) Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia. Eur J Haematol 112(1):83\u201393. https:\/\/doi.org\/10.1111\/ejh.14104","journal-title":"Eur J Haematol"},{"issue":"11","key":"4342_CR18","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, Zheng Y, He Y, Hu Z, Pei K, Luo M, Li C (2022) Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36(11):2596\u20132604. https:\/\/doi.org\/10.1038\/s41375-022-01703-0","journal-title":"Leukemia"},{"issue":"8","key":"4342_CR19","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei K, Xu H, Wang P, Gan W, Hu Z, Su X, Zhang H, He Y (2023) Anti-CLL1-based CAR T-cells with 4\u20131-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med 12(8):9655\u20139661. https:\/\/doi.org\/10.1002\/cam4.5916","journal-title":"Cancer Med"},{"key":"4342_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491341","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang M, Zhang X, Wang J, Lu W, Xiao X, Lyu H, He X, Pu Y, Meng J, Lyu C, Cao X, Zhao M (2024) Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Front Immunol 15:1491341. https:\/\/doi.org\/10.3389\/fimmu.2024.1491341","journal-title":"Front Immunol"},{"issue":"8","key":"4342_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S, Rothamel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T (2021) CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood 137(8):1037\u20131049. https:\/\/doi.org\/10.1182\/blood.2020006921","journal-title":"Blood"},{"issue":"1","key":"4342_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M (2019) Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33(1):64\u201374. https:\/\/doi.org\/10.1038\/s41375-018-0180-3","journal-title":"Leukemia"},{"key":"4342_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112259","author":"E Laborda","year":"2017","unstructured":"Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS (2017) Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18112259","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4342_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-025-00934-1","volume":"6","author":"S Ikeda","year":"2025","unstructured":"Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, Yaga M, Inada Y, Uehara H, Matsubara M, Tachikawa M, Suga M, Kida S, Shibata K, Tsutsumi K, Fukushima K, Fujita J, Ueda T, Kusakabe S, Hino A, Ichii M, Hirose A, Nakamae H, Hino M, Nakao T, Inoue M, Yoshihara K, Yoshihara S, Ueda S, Tachi T, Kuroda H, Murakami K, Kijima N, Kishima H, Igashira E, Murakami M, Takiuchi T, Kimura T, Hiroshima T, Kimura T, Shintani Y, Imai C, Yusa K, Mori R, Ogino T, Eguchi H, Takeda K, Oji Y, Kumanogoh A, Takagi J, Hosen N (2025) CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nat Cancer 6(4):595\u2013611. https:\/\/doi.org\/10.1038\/s43018-025-00934-1","journal-title":"Nat Cancer"},{"key":"4342_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R (2021) Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-26683-0","journal-title":"Nat Commun"},{"issue":"1","key":"4342_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN (2022) Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5. https:\/\/doi.org\/10.1038\/s41408-021-00603-3","journal-title":"Blood Cancer J"},{"issue":"3","key":"4342_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"4342_CR28","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H (2021) Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res 27(13):3549\u20133555. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4543","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4342_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr. (2016) High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30(6):1355\u20131364. https:\/\/doi.org\/10.1038\/leu.2016.35","journal-title":"Leukemia"},{"issue":"9","key":"4342_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ (2019) Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 25(9):1408\u20131414. https:\/\/doi.org\/10.1038\/s41591-019-0549-5","journal-title":"Nat Med"},{"issue":"7954","key":"4342_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615(7954):920\u2013924. https:\/\/doi.org\/10.1038\/s41586-023-05812-3","journal-title":"Nature"},{"key":"4342_CR32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283437","author":"DV Jeyaraju","year":"2023","unstructured":"Jeyaraju DV, Alapa M, Polonskaia A, Risue\u00f1o A, Subramanyam P, Anand A, Ghosh K, Kyriakopoulos C, Hemerich D, Hurren R, Wang X, Gronda M, Ahsan A, Chiu H, Thomas G, Lind EF, Menezes DL, Schimmer AD, Hagner PR, Gandhi A, Thakurta AG (2023) Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283437","journal-title":"Haematologica"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04342-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:14:28Z","timestamp":1772442868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04342-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04342-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.H. has applied for a Japanese patent entitled Antibodies against CLL-1 through the University of Osaka Office for University\u2013Industry Collaboration. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All mouse experiments were approved by the Administrative Panel on Laboratory Animal Care at University of Osaka (Protocol No. 03\u2013045-023). Human sample collection and experimental procedures were approved by the Institutional Review Board of University of Osaka, and written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"92"}}